Hikma to distribute Eisai’s Fycompa in Middle East

13 October 2014

Fast-growing Jordan-based drugmaker Hikma Pharmaceuticals (LSE: HIK) has entered into a partnership with Japanese pharma major Eisai (TYO: 4523) for the distribution of Fycompa(perampanel), Eisai’s first-in-class epilepsy treatment, in the Middle East.

The partnership will commence immediately, with perampanel launches throughout the region expected to follow in 2015. Perampanel is indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalized seizures, in patients with epilepsy aged 12 years and older. Financial terms of the collaboration were not disclosed.

According to the companies, perampanel is the only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a protein in the brain which plays a critical role in the spread of seizures.This mechanism of action is different to other currently available AEDs. In addition, perampanel has the added benefit of convenient, once-daily dosing at bedtime.

Territories covered by deal

Countries covered by the five-year partnership will include the Kingdom of Saudi Arabia, the United Arab Emirates, Jordan, Kuwait, Bahrain, Oman, Qatar, Sudan, Iraq, Libya and Yemen. Perampanel was approved by the European Commission in July 2012 and the US Food and Drug Administration in October 2012. Discovered and developed by Eisai in Europe and Japan, perampanel is manufactured in the UK.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical